Dogwood Therapeutics Q4 net loss narrows on lower expenses

Dogwood Therapeutics

18/03/2026 12:38

Overview

US biotechnology developer's Q4 net loss narrowed yr/yr due to lower administrative expenses

Full year net loss widened, driven by increased R&D expenses for clinical trials and licensing

Company completed $26.9 mln financing in Jan 2026, expects cash to fund operations into Q4 2026

Outlook

Company expects top-line results from Halneuron Phase 2b trial in Q3 2026

Dogwood says current cash and recent financing expected to fund operations into Q4 2026

Result Drivers

ADMINISTRATIVE COSTS - Lower Q4 administrative expenses, mainly due to absence of nonrecurring transaction costs from prior business combination and reduced personnel costs

Company press release: ID:nGNX4Fjz54

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.26
Q4 Net Income
-$3.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $15.00, about 365.8% above its March 17 closing price of $3.22

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)